Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many pati...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chandni Bardolia, Nishita Shah Amin, Jacques Turgeon
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	ezetimibe PCSK9 inhibitors alirocumab evolocumab bempedoic acid inclisiran Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/66534c214f3c452c9cb96c64a988deac
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66534c214f3c452c9cb96c64a988deac
record_format	dspace
spelling	oai:doaj.org-article:66534c214f3c452c9cb96c64a988deac2021-11-17T05:31:59ZEmerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol2297-055X10.3389/fcvm.2021.789931https://doaj.org/article/66534c214f3c452c9cb96c64a988deac2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fcvm.2021.789931/fullhttps://doaj.org/toc/2297-055XLow-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many patients do not achieve their cholesterol goals or are unable to tolerate this drug class due to adverse drug events. Recent studies of non-statin cholesterol lowering drugs (i.e., ezetimibe, PCSK9 inhibitors) have demonstrated cardiovascular benefits; and new drugs [i.e., bempedoic acid (BDA), inclisiran] have produced promising results in pre-clinical and clinical outcome trials. This narrative review aims to discuss the place in therapy of ezetimibe, PCSK9 inhibitors, BDA, and inclisiran and describe their relative pharmacokinetic (PK) profiles, efficacy and safety as monotherapy and combination therapy, and cardiovascular benefit(s) when used for hypercholesterolemia.Chandni BardoliaNishita Shah AminJacques TurgeonJacques TurgeonFrontiers Media S.A.articleezetimibePCSK9 inhibitorsalirocumabevolocumabbempedoic acidinclisiranDiseases of the circulatory (Cardiovascular) systemRC666-701ENFrontiers in Cardiovascular Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ezetimibe PCSK9 inhibitors alirocumab evolocumab bempedoic acid inclisiran Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	ezetimibe PCSK9 inhibitors alirocumab evolocumab bempedoic acid inclisiran Diseases of the circulatory (Cardiovascular) system RC666-701 Chandni Bardolia Nishita Shah Amin Jacques Turgeon Jacques Turgeon Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
description	Low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for the development of atherosclerotic cardiovascular disease. Statins have been the gold standard for managing cholesterol levels and reducing the risks associated with atherosclerotic cardiovascular disease; however, many patients do not achieve their cholesterol goals or are unable to tolerate this drug class due to adverse drug events. Recent studies of non-statin cholesterol lowering drugs (i.e., ezetimibe, PCSK9 inhibitors) have demonstrated cardiovascular benefits; and new drugs [i.e., bempedoic acid (BDA), inclisiran] have produced promising results in pre-clinical and clinical outcome trials. This narrative review aims to discuss the place in therapy of ezetimibe, PCSK9 inhibitors, BDA, and inclisiran and describe their relative pharmacokinetic (PK) profiles, efficacy and safety as monotherapy and combination therapy, and cardiovascular benefit(s) when used for hypercholesterolemia.
format	article
author	Chandni Bardolia Nishita Shah Amin Jacques Turgeon Jacques Turgeon
author_facet	Chandni Bardolia Nishita Shah Amin Jacques Turgeon Jacques Turgeon
author_sort	Chandni Bardolia
title	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
title_short	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
title_full	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
title_fullStr	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
title_full_unstemmed	Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
title_sort	emerging non-statin treatment options for lowering low-density lipoprotein cholesterol
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/66534c214f3c452c9cb96c64a988deac
work_keys_str_mv	AT chandnibardolia emergingnonstatintreatmentoptionsforloweringlowdensitylipoproteincholesterol AT nishitashahamin emergingnonstatintreatmentoptionsforloweringlowdensitylipoproteincholesterol AT jacquesturgeon emergingnonstatintreatmentoptionsforloweringlowdensitylipoproteincholesterol AT jacquesturgeon emergingnonstatintreatmentoptionsforloweringlowdensitylipoproteincholesterol
_version_	1718425863456817152

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol

Ejemplares similares